RecruitingNot ApplicableNCT06684028

PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors


Sponsor

Affiliated Hospital of Jiangnan University

Enrollment

30 participants

Start Date

Jul 12, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

To investigate the biological distribution of a new tracer 68Ga-FAPI-JNU in the primary, metastatic and normal tissues of patients with malignant tumors, and to evaluate the biological distribution of 68GA-FAPI-JNU with standardized uptake values.


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Inclusion Criteria4

  • The subjects sign the informed consent voluntarily and can complete the test according to the protocol requirements;
  • Age 18-85 years old, male or female;
  • Clinically diagnosed as malignant tumor, diagnostic criteria refer to biopsy or other imaging such as CT and MRI;
  • ECOG score is 0-3 points;

Exclusion Criteria4

  • Patients with a history or allergic constitution to any component of the developer, including alcohol;
  • pregnant or lactating women;
  • Patients with mental illness or related history;
  • Patients who cannot or cannot undergo a PET/CT scan;

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG68Ga-FAPI-JNU

Patients will receive the novel tracer 68Ga-FAPI-JNU dose of approximately 2-5 mCi per person


Locations(1)

Affiated Hospital of Jiangnan University

Wuxi, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06684028


Related Trials